As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of caplacizumab within its marketing authorisation for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
Please note that following on from advice received from the company this appraisal has now been rescheduled back into the work programme. The appraisal is now anticipated to being in early August 2019.